Your activity: 123 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Checkpoint inhibitors by mechanism and indication

Checkpoint inhibitors by mechanism and indication
Drug mechanism Drug name First indication
Anti PD-1 Nivolumab Melanoma[1]
Pembrolizumab Melanoma[2]
Cemiplimab Cutaneous squamous cell carcinoma[3]
Dostarlimab Endometrial cancer[4]
Anti PD-L1 Atezolizumab Urothelial carcinoma[5]
Avelumab Merkel cell carcinoma[6]
Durvalumab Urothelial carcinoma[7]
Anti CTLA-4 Ipilimumab Melanoma[8]
PD-1: programmed cell death 1; PD-L1: programmed cell death ligand 1; CTLA-4: cytotoxic T lymphocyte-associated antigen 4.
References:
  1. Opdivo (nivolumab) injection, for intravenous use. US FDA approved product information; Princeton, NJ: Bristol-Myers Squibb Company; April 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s058lbl.pdf.
  2. Keytruda (pembrolizumab) for injection, for intravenous use. US FDA approved product information; Carlow, Ireland: Merck Sharp and Dohme Corp; January 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s066lbl.pdf.
  3. Libtayo (cemiplimab-rwlc) injection, for intravenous use. US FDA approved product information; Tarrytown, NY: Regeneron Pharmaceuticals, Inc; June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761097s005lbl.pdf.
  4. Jemperli (dostarlimab-gxly) injection, for intravenous use. US FDA approved product information; Philadelphia, PA: GlaxoSmithKline LLC; May 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf.
  5. Tecentriq (atezolizumab) injection, for intravenous use. US FDA approved product information; South San Francisco, CA: Genentech, Inc; March 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf.
  6. Bavencio (avelumab) injection, for intravenous use. US FDA approved product information; Rockland, MD: EMD Serono, Inc; May 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761049s006lbl.pdf.
  7. Imfinzi (durvalumab) injection, for intravenous use. US FDA approved product information; Wilmington, DE: AstraZeneca Pharmaceuticals; April 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf.
  8. Yervoy (ipilimumab) injection, for intravenous use. US FDA approved product information; Princeton, NJ: Bristol-Myers Squibb Company; October 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf.
Graphic 130841 Version 2.0